Sartorius-Logo_BIA-separations-Logo_Part-of Sartorius

BIA Separations

Lead Partner

BIA Separations, recently acquired by Sartorius, develops and manufactures market-leading CIM® monolithic chromatographic columns for purification and analysis of large biomolecules, such as viruses, plasmids and mRNA, which are applied in cell and gene therapies.  BIA's technology for manufacturing-scale purification is already used in production of the first commercialized advanced therapeutics; BIA also has a keen presence with novel drug candidates in the clinical pipeline.  Expecting continued strong double-digit sales growth over the next few years, BIA earned sales revenue approx. 25 million Euros in 2020, contributing to Sartorius Bioprocess Solutions, part of the Sartorius Group.



Hosting Partner

Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to prevent illness and enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. These enable our customers to commercialize their discoveries and innovations in the healthcare sector.

Founded in 1897 in the Swiss Alps, today Lonza operates across five continents. With approximately 14,000 full-time employees, we are built from high-performing teams and of individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 4.5 billion in 2020 with a CORE EBITDA of CHF 1.4 billion.

Follow @Lonza on LinkedIn
Follow @LonzaGroup on Twitter


Screen Shot 2021-04-26 at 12.13.23 PM

AexeRNA Therapeutics

Innovation Partner

AexeRNA Therapeutics is developing mRNA therapeutics utilizing its proprietary next generation tunable and highly potent Lipid Nanoparticle (LNP) nucleic acid delivery system. The AexLNP system was developed by Michael Buschmann at George Mason University and Drew Weissman at the University of Pennsylvania. In addition to our own therapeutic pipeline, AexeRNA provides our partners with a turn-key, best-in-class, IP-independent, mRNA LNP delivery platform technology for their mRNA therapeutics programs.